Citius Oncology, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Gross Margin | — | — | — | — | — |
| Operating Expenses | |||||
| Research & Development | $6.4M | $4.9M | $4.2M | — | — |
| SG&A Expense | $8.8M | $8.1M | $1.0M | $138.1K | $10.1K |
| Operating Income | $-23.5M | $-20.6M | $-1.0M | $-138.1K | $-10.1K |
| Operating Margin | — | — | — | — | — |
| Interest Expense | $218.0K | — | — | — | — |
| Pretax Income | $-23.7M | $-20.6M | $-12.1M | — | — |
| Income Tax Expense | $1.1M | $576.0K | $576.0K | — | — |
| Net Income | $-24.8M | $-21.1M | $2.4M | $380.8K | $-10.1K |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | $-0.34 | $-0.31 | $0.03 | $0.00 | $0.00 |
| EPS (Diluted) | $-0.34 | $-0.31 | $0.03 | $0.00 | — |
| Shares Outstanding (Basic) | 73.3M | 68.1M | 66.0M | 67.1M | 86.3M |
| Shares Outstanding (Diluted) | 73.3M | 68.1M | 66.0M | 67.1M | 86.3M |
| Dividends Per Share | — | — | — | — | — |